聚乳酸在中药浓缩胶囊中的应用前景探索

Exploration of the Application Prospects of Polylactic Acid (PLA) in Concentrated Traditional Chinese Medicine Capsules

摘要: 中药现代化进程中，剂型创新是突破传统制剂局限性、实现精准化治疗的核心路径。聚乳酸(PLA)作为一种生物可降解材料，凭借其独特的物理化学特性与动态响应机制，为中药浓缩制剂的载体革新提供了革命性解决方案。本文聚焦PLA的分子拓扑设计(如L/D-乳酸比例调控)与多级结构演化(梯度结晶、介观球晶优化)，系统阐释其与中药复方多组分复杂体系的适配性机理：通过构建“氢键网络–疏水微区”双位点结合模型，PLA可精准调控亲/疏水成分的时序释放，复现“君臣佐使”的配伍逻辑；其pH响应特性与酶促降解机制的协同作用，则实现了从胃部保护到肠道靶向的智能递送，显著提升黄酮类等敏感成分的生物利用度。结合缓释实验与临床前研究，提出“PLA包衣 + 中药浓缩提取”的制剂开发范式——通过分子量梯度设计与结晶度调控，使载体降解动力学与中药成分的肠肝循环周期动态匹配，血药浓度波动系数降低至传统制剂的1/3。这一路径不仅为慢性病的长效调理(如高血压晨峰现象调控)提供技术支撑，更通过“结构预设–动态响应–功能输出”的可编程设计，推动中药制剂向精准用药时代迈进。本研究从材料–药理协同视角，为中医药理论的现代化诠释与产业化升级提供了跨学科范式。

Abstract: In the process of modernizing traditional Chinese medicine (TCM), dosage form innovation represents a core pathway to break through the limitations of traditional formulations and achieve precision therapy. As a biodegradable material, polylactic acid (PLA), with its unique physicochemical properties and dynamic response mechanisms, has provided a revolutionary solution for the carrier innovation of concentrated TCM preparations. This paper focuses on the molecular topology design of PLA (such as the regulation of L/D-lactic acid ratio) and multilevel structural evolution (gradient crystallization, mesoscopic spherulite optimization), systematically explaining its adaptation mechanism with the complex multi-component system of TCM compound formulas: By constructing a “hydrogen bond network-hydrophobic microdomain” dual-site binding model, PLA can precisely regulate the time-sequential release of hydrophilic/hydrophobic components, reproducing the compatibility logic of “sovereign, minister, assistant, and guide”; the synergistic effect of its pH-responsive properties and enzymatic degradation mechanism enables intelligent delivery from gastric protection to intestinal targeting, significantly improving the bioavailability of sensitive components such as flavonoids. Combining sustained-release experiments and preclinical studies, a formulation development paradigm of “PLA coating + concentrated TCM extraction” is proposed—through molecular weight gradient design and crystallinity regulation, the degradation kinetics of the carrier are dynamically matched with the enterohepatic circulation cycle of TCM components, reducing the blood drug concentration fluctuation coefficient to 1/3 of that of traditional formulations. This approach not only provides technical support for the long-acting conditioning of chronic diseases (such as the regulation of morning blood pressure surge in hypertension), but also promotes TCM formulations to enter the era of precision medication through “structure-preset - dynamic response - function output” programmable design. This study provides an interdisciplinary paradigm for the modern interpretation of TCM theories and industrial upgrading from the perspective of material-pharmacology synergy.